GSK Licenses Anti-CD20 Agent; Efficacy Relative To Rituxan Touted

Genmab's HuMax-CD20 could be more efficacious than Genentech/Biogen Idec's Rituxan due to the potential for greater activation of immune system defenses, the firm said Dec. 19 after announcing it had reached a codevelopment deal for ofatumumab with GlaxoSmithKline